 The proposed theory is based on combination of radiation therapy with usual targeted therapies capable of ADCC Antibody-Dependant Cell Cytotoxicity. This association could enhance in a additivesynergistic way the benefic impact of immune system activation on tumor control. Stereotactic Body Radio-Therapy SBRT will be combined with the first line chemotherapy for metastatic breast, colorectal or VADS upper aerodigestive tract cancers. The IRAM study objective is to highlight a possible abscopal effect of this combination for metastatic cancer patients. 